Mammoth Biosciences, a South San Francisco, CA-based developer of a CRISPR-based disease detection platform, raised $45m in Series B funding.
The round was led by Decheng Capital with participation from Mayfield, NFX, Verily, Brook Byers, Plum Alley, Pacific 8, aMoon, and others.
The company will use the funds to accelerate development of CRISPR diagnostics and next-generation CRISPR products as it extends its platform to include gene-editing and therapeutics as well.
Co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington, Mammoth Biosciences leverages its internal research and development and exclusive licensing to Cas12, Cas13 and Cas14 to provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more.
The company is also exploring deep partnerships with biotech and pharmaceutical companies to leverage the Mammoth CRISPR platform to advance healthcare and deliver benefits to patients.
Recently, industry veterans including Peter Nell, previously a cofounder of Casebia (a joint venture between Bayer and CRISPR Therapeutics) and Ted Tisch, previously an executive at Synthego and Bio-Rad, have joined the company to accelerate its growth as Chief Business Officer and Chief Operating Officer, respectively. Grail co-founder and previous Illumina board member Jeff Huber has joined the company’s board as an independent director and the Dean of the Stanford University School of Medicine, Lloyd Minor, has joined the Mammoth advisory board.